Featured Research

from universities, journals, and other organizations

VEGF may not be relevant biomarker for advanced prostate cancer

Date:
April 29, 2013
Source:
Thomas Jefferson University
Summary:
The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers found.

The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.

VEGF, or vascular endothelial growth factor, induces blood vessel growth, a process known as angiogenesis, which is a key element in solid tumor growth and metastasis. It is overexpressed, along with its receptors, in various cancers, including breast, renal cell carcinoma and gliomas, and has been shown to help predict response to certain drugs. However, conflicting data in the literature has left the role of VEGF in prostate cancer as a useful biomarker unclear and controversial.

Here, in one of the largest studies of VEGF expression in prostate cancer, senior author Adam P. Dicker, MD, PhD, Chair of the Department of Radiation Oncology at Jefferson, and colleagues retrospectively analyzed data from two groups of men with locally advanced prostate cancer: those who had only radiation therapy and those who had short-term neoadjuvant and concurrent androgen deprivation therapy and radiation therapy.

Data was collected using pathologic material of over 100 men from the Radiation Therapy Oncology Group 8610 phase III randomized control trial to explore VEGF's potential as a biomarker, one that could be used to improve the treatment of prostate cancer patients through better targeted therapies.

Based on the results, however, researchers posit that the VEGF protein may not be a relevant biomarker for this patient group.

They found no statistically significant difference in pre-treatment characteristics among men with varying VEGF levels and no correlation between VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or biochemical failure.

What's more, there was no difference between the two treatment arms, those who had androgen therapy and radiation therapy and those who just had radiation. The median follow up time was for all surviving patients was 12.2 years.

"VEGF in this disease does not have a driver role," said Dr. Dicker. "The clinical trials using VEGF inhibitors did not have clinical benefit, so this study confirms that this is not a path forward to tacking this disease."

The results are not definitive statements about VEGF, the authors explain, but reporting on this well-characterized population with long-term follow is a significant contribution to the literature.

"This study is among the larger studies of VEGF expression in prostate cancer, and we urge the research community to avoid the misrepresentation of the literature with a lack of publication of even well-designed large negative studies, a publication bias against negative trials, as the current literature in this area appears to be predominated by only small exploratory positive trials, with a lack of subsequent confirmation with larger, longer prospectively designed trials," the authors write.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Larry Pan, Seunghee Baek, Pamela R Edmonds, Mack Roach, Harvey Wolkov, Satish Shah, Alan Pollack, M Elizabeth Hammond, Adam P Dicker. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiation Oncology, 2013; 8 (1): 100 DOI: 10.1186/1748-717X-8-100

Cite This Page:

Thomas Jefferson University. "VEGF may not be relevant biomarker for advanced prostate cancer." ScienceDaily. ScienceDaily, 29 April 2013. <www.sciencedaily.com/releases/2013/04/130429133542.htm>.
Thomas Jefferson University. (2013, April 29). VEGF may not be relevant biomarker for advanced prostate cancer. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2013/04/130429133542.htm
Thomas Jefferson University. "VEGF may not be relevant biomarker for advanced prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2013/04/130429133542.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
How Mt. Everest Helped Scientists Research Diabetes

How Mt. Everest Helped Scientists Research Diabetes

Newsy (Apr. 15, 2014) British researchers were able to use Mount Everest's low altitudes to study insulin resistance. They hope to find ways to treat diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins